GlobeNewswire Inc | Jan 17, 2022 06:00AM EST

January 17, 2022

MELBOURNE, Australia, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce that under the Australian Governments Research and Development Income Tax Concession incentive program, the Company has received a cash refund of AUD $306,154 for eligible research and development expenditure incurred during the 2021 Financial Year.

This release has been authorized by the directors of Immuron Limited.

COMPANY CONTACT: US INVESTOR CONTACT

Dr Jerry Kanellos, Ph.D. Dave Gentry, CEO Chief Executive Officer RedChip Companies Inc.Ph: +61 (0)3 9824 5254 +1-407-491-4498info@immuron.com dave@redchip.com

About ImmuronImmuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.

For more information visit: http://www.immuron.com